SCHEMBL2207912

SCHEMBL2207912

CN(C)CC1c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2CCN1Cc1cocn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.54
KCNH2 Q12809 1/20 0.52
SCD O00767 1/20 0.38
KCNE1 P15382 1/20 0.37
CCR1 P32246 1/20 0.37
KCNQ1 P51787 1/20 0.37
CALCA P06881 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ERCC1 P07992 1/20 0.34
FEN1 P39748 1/20 0.34
ERCC4 Q92889 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
MAPT P10636 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2204844 0.88 CYP2C9 (0.53) CYP2C9KCNH2SCDKCNE1CCR1
SCHEMBL2207582 0.86 KCNH2 (0.52) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL2207201 0.83 KCNH2 (0.61) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL2206748 0.81 CYP2C9 (0.64) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL2208031 0.81 KCNH2 (0.59) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL2531997 0.81 KCNH2 (0.52) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL2207126 0.80 KCNH2 (0.62) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL2209452 0.80 KCNH2 (0.57) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL12244554 0.78 KCNH2 (0.59) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL2203693 0.78 CYP2C9 (0.46) CYP2C9KCNH2SCDKCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253681-A1 HIV Integrase Inhibitors MSD ITALIA S.R.L. (IT) 2009-10-08 US claimed
EP-1866313-A1 HIV INTEGRASE INHIBITORS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2007-12-19 EP claimed
WO-2006103399-A1 HIV INTEGRASE INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2006-10-05 WO claimed
US-20110257162-A1 HIV INTEGRASE INHIBITORS SUMMA VINCENZO 2011-10-20 US disclosed
US-7981879-B2 HIV integrase inhibitors Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) 2011-07-19 US disclosed
US-7981879-B2 HIV integrase inhibitors Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) 2011-07-19 US disclosed
US-20090253681-A1 HIV Integrase Inhibitors MSD ITALIA S.R.L. (IT) 2009-10-08 US disclosed
US-20090253681-A1 HIV Integrase Inhibitors MSD ITALIA S.R.L. (IT) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257162-A1 HIV INTEGRASE INHIBITORS REV1, CDK9, INTS9 CYP2C9 672/4885KCNH2 2918/4885SCD 2989/4885
US-20090253681-A1 HIV Integrase Inhibitors REV1, INTS9, H1-10 CYP2C9 449/4885KCNH2 3625/4885SCD 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.